Back to Search
Start Over
Histamine-Releasing Factor, a New Therapeutic Target in Allergic Diseases
- Source :
- Cells
- Publication Year :
- 2019
- Publisher :
- MDPI AG, 2019.
-
Abstract
- Histamine-releasing activities on human basophils have been studied as potential allergy-causing agents for four decades. An IgE-dependent histamine-releasing factor (HRF) was recently shown to interact with a subset of immunoglobulins. Peptides or recombinant proteins that block the interactions between HRF and IgE have emerged as promising anti-allergic therapeutics, as administration of them prevented or ameliorated type 2 inflammation in animal models of allergic diseases such as asthma and food allergy. Basic and clinical studies support the notion that HRF amplifies IgE-mediated activation of mast cells and basophils. We discuss how secreted HRF promotes allergic inflammation in vitro and in vivo complex disease settings.
- Subjects :
- Models, Molecular
0301 basic medicine
Allergy
Protein Conformation
FcεRI
mast cells
Inflammation
Review
Immunoglobulin E
Allergic inflammation
Structure-Activity Relationship
03 medical and health sciences
0302 clinical medicine
Food allergy
In vivo
Biomarkers, Tumor
Hypersensitivity
medicine
Animals
Humans
Anti-Asthmatic Agents
Molecular Targeted Therapy
biology
business.industry
Tumor Protein, Translationally-Controlled 1
General Medicine
Allergens
allergy
medicine.disease
In vitro
3. Good health
030104 developmental biology
030220 oncology & carcinogenesis
Immunology
HRF
biology.protein
translationally controlled tumor protein (TCTP)
Disease Susceptibility
IgE
Protein Multimerization
medicine.symptom
Antibody
business
basophils
Biomarkers
Protein Binding
Subjects
Details
- ISSN :
- 20734409
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Cells
- Accession number :
- edsair.doi.dedup.....7551ca4b8ed0bb9d9bdaa4ae38d67712